Investigating how Mre11 affects DNA damage responses in breast cancer
Mre11-Dependent DNA Damage Responses in Breast Cancer Pathogenesis
This study is looking at how a protein called Mre11 affects DNA damage in breast cancer, especially in a type called triple-negative breast cancer, to find new ways to improve treatment for patients.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project ID | NIH-11045048 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of the Mre11 protein in the DNA damage response specifically in breast cancer. It examines how deficiencies in Mre11 can lead to chromosomal instability and contribute to the development of triple-negative breast cancer (TNBC). The study uses advanced techniques such as time-lapse microscopy and single-cell whole genome sequencing to analyze the effects of Mre11 and p53 deficiencies on cancer progression. By studying these mechanisms in murine models, the research aims to uncover potential therapeutic targets for improving treatment outcomes in breast cancer patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with triple-negative breast cancer or those with a family history of breast cancer.
Not a fit: Patients with non-breast cancer conditions or those with hormone receptor-positive breast cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for treating breast cancer, particularly in patients with triple-negative breast cancer.
How similar studies have performed: Previous research has shown promising results in understanding DNA damage responses in cancer, suggesting that this approach could yield valuable insights.
Where this research is happening
Chapel Hill, United States
- Univ of North Carolina Chapel Hill — Chapel Hill, United States (Active)
Researchers
- Principal investigator: Gupta, Gaorav P. — Univ of North Carolina Chapel Hill
- Study coordinator: Gupta, Gaorav P.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.